Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Recurrence 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphedema 1Locally Advanced Bladder Cancer 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cisplatin 109Radiotherapy 100Fluorouracil 90Paclitaxel 75Oxaliplatin 63Docetaxel 56Carboplatin 55Irinotecan 41Esophagectomy 41Leucovorin 40Capecitabine 39Surgical Procedures, Operative 36Radiation 36Drug Therapy 31Neoadjuvant Therapy 25Chemoradiotherapy 18Cetuximab 18S 1 (combination) 17pembrolizumab 16camrelizumab 16Nivolumab 15Magnetic Resonance Spectroscopy 15Bevacizumab 15Blood Specimen Collection 14Surveys and Questionnaires 12Radiotherapy, Intensity-Modulated 12Immunotherapy 11Epirubicin 11Biopsy 11Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Neoplasms × Pharmaceutical Preparations × Clear all
NCT00318903 2023-05-25

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

University of Alabama at Birmingham

Phase 2 Completed
25 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡